stella
beta
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations — Stella
Recruiting
Back to Chronic Myelomonocytic Leukemia trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
M D Anderson Cancer Center, Houston, Texas
View full record on ClinicalTrials.gov